Insmed Gains FDA Priority Review for ARIKAYCE sNDA

Insmed's parallel regulatory strategy across the U.S. and Japan is producing measurable outcomes that QA directors and regulatory affairs leads at specialty respiratory programs should track closely. Within a single quarter, the company secured FDA Priority Review for an ARIKAYCE supplemental NDA and completed the first commercial launch of a MHLW-approved treatment for non-cystic fibrosis bronchiectasis in Japan.

The FDA accepted Insmed's sNDA for ARIKAYCE (amikacin liposome inhalation suspension) in September 2026, targeting expanded use in Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial regimen. A PDUFA action date of January 28, 2027 has been set under Priority Review. For regulatory teams managing lifecycle management filings, the acceptance signals that the agency found the submission sufficiently complete to proceed, a checkpoint that carries weight given the complexity of inhaled antibiotic dossiers under 21 CFR Part 314.

Separately, Japan's Ministry of Health, Labour and Welfare approved BRINSUPRI Tablets 25 mg (brensocatib hydrate) in August 2026 for NCFB in adults and pediatric patients aged 12 and older. Insmed launched the product in Japan in October 2026, making it the first and only MHLW-approved therapy for NCFB. For operations and supply chain leads supporting multi-market launches, the compressed timeline between approval and commercial availability in a market with stringent post-marketing surveillance requirements reflects deliberate pre-launch manufacturing readiness.

On the data submission front, Insmed plans to file Phase 3 ENCORE study results with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) in Q4 2026, seeking label expansion for ARIKAYCE to all MAC lung disease patients, not only those with refractory disease. That submission, if accepted, would broaden the eligible population and carry downstream implications for manufacturing scale and batch release capacity.

Commercially, BRINSUPRI generated $400.1 million in Q3 2026 revenue, up 29% quarter-over-quarter, while ARIKAYCE posted $124.4 million, up 9% year-over-year. Full-year 2026 guidance has been raised to $1.35–$1.4 billion for BRINSUPRI and $460–$470 million for ARIKAYCE. Phase 3 enrollment in the PALM-ILD study for treprostinil palmitil inhalation powder (TPIP) has exceeded 35%, with completion expected in the first half of 2028.

The PDUFA date of January 28, 2027 for the ARIKAYCE sNDA will serve as the near-term regulatory checkpoint against which Insmed's MAC lung disease manufacturing and distribution readiness will be measured.

Source: Insmed Incorporated via PR Newswire, October 29, 2026.